Recommendations on percutaneous coronary intervention for the reperfusion of acute ST elevation myocardial infarction

Little information is currently available from the various societies of cardiology on primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI). Since primary PCI is the main method of reperfusion in AMI in many centres, and since of all cardiac emergencies AMI represents the most urgent situation for PCI, recommendations based on scientific evidence and expert experience would be useful for centres practising primary PCI, or those looking to establish a primary PCI programme. To this aim, a task force for primary PCI in AMI was formed to develop a set of recommendations to complement and assist clinical judgment. This paper represents the product of their recommendations.

El programa de cooperación interuniversitària de la AECID: 18 años de historia interrumpidos por la crisis econòmica

Nota on es vol fer constar la cancel·lació del “Programa de Cooperación Interuniversitaria” conegut per l'acrònim “PCI” de l' “Agencia Española de Cooperación Internacional para el Desarrollo” (AECID), un dels programes més exitosos y de més llarga tradició de la cooperació espanyola

Development of an epidermal growth factor derivative with EGFR blocking activity.

The members of the epidermal growth factor (EGF)/ErbB family are prime targets for cancer therapy. However, the therapeutic efficiency of the existing anti-ErbB agents is limited. Thus, identifying new molecules that inactivate the ErbB receptors through novel strategies is an important goal on cancer research. In this study we have developed a shorter form of human EGF (EGFt) with a truncated C-terminal as a novel EGFR inhibitor. EGFt was designed based on the superimposition of the three-dimensional structures of EGF and the Potato Carboxypeptidase Inhibitor (PCI), an EGFR blocker previously described by our group. The peptide was produced in E. coli with a high yield of the correctly folded peptide. EGFt showed specificity and high affinity for EGFR but induced poor EGFR homodimerization and phosphorylation. Interestingly, EGFt promoted EGFR internalization and translocation to the cell nucleus although it did not stimulate the cell growth. In addition, EGFt competed with EGFR native ligands, inhibiting the proliferation of cancer cells. These data indicate that EGFt may be a potential EGFR blocker for cancer therapy. In addition, the lack of EGFR-mediated growth-stimulatory activity makes EGFt an excellent delivery agent to target toxins to tumours over-expressing EGFR.

Eficacia del kinesiotape como terapia complementaria en niños que presentan espasticidad.

¿Se obtiene una mejora de resultados añadiendo Kinesiotape a sujetos que presentan PCI espástica comparado con un tratamiento convencional de fisioterapia? Objetivos: Evaluar la efectividad del Kinesiotape en cuanto a disminución de espasticidad y tono muscular, mejora de calidad de vida y aumento del rango articular. Material y métodos: se buscará una muestra de 238 sujetos con PCI espástica entre 5 y 20 años y que presenten una sinergia flexora en extremidad superior. Como criterios de exclusión se consideran: cualquier contraindicación del Kinesiotape, intervención quirúrgica de extremidad superior, consumo de neurotoxinas, bloqueantes nerviosos con agentes neurolíticos, relajantes musculares y pacientes que hayan sido tratados mediante Toxina Botulínica en extremidad superior. Los sujetos serán aleatoriamente distribuidos en dos grupos; un grupo control (n = 119) el cual realiza tratamiento específico de Bobath y un grupo experimental (n = 119) el cual realiza el tratamiento específico de Bobath añadiendo el Kinesiotape en la musculatura del bíceps braquial. Esta intervención durará ocho semanas y se reevaluarán los resultados en un periodo de seis meses y a los doce meses. Para ello se utilizaran las siguientes escalas: para la espasticidad se utilizarán las escalas de Tardieu - Held y la de Aswhorth modificada. Para medir la independencia del niño se emplearán la escala Pediatric Evaluation of Disability Inventory (PEDI), para conocer el rango articular se utilizarán un goniómetro de brazos y para determinar la actividad eléctrica del tono muscular la electromiografía (EMG).

Prehospital ticagrelor in ST-segment elevation myocardial infarction

Background:The direct-acting platelet P2Y receptor antagonist ticagrelor can reduce the incidence of major adverse cardiovascular events when administered at hospital admission to patients with ST-segment elevation myocardial infarction (STEMI). Whether prehospital administration of ticagrelor can improve coronary reperfusion and the clinical outcome is unknown. Methods: We conducted an international, multicenter, randomized, double-blind study involving 1862 patients with ongoing STEMI of less than 6 hours' duration, comparing prehospital (in the ambulance) versus in-hospital (in the catheterization laboratory) treatment with ticagrelor. The coprimary end points were the proportion of patients who did not have a 70% or greater resolution of ST-segment elevation before percutaneous coronary intervention (PCI) and the proportion of patients who did not have Thrombolysis in Myocardial Infarction flow grade 3 in the infarct-related artery at initial angiography. Secondary end points included the rates of major adverse cardiovascular events and definite stent thrombosis at 30 days. Results: The median time from randomization to angiography was 48 minutes, and the median time difference between the two treatment strategies was 31 minutes. The two coprimary end points did not differ significantly between the prehospital and in-hospital groups. The absence of ST-segment elevation resolution of 70% or greater after PCI (a secondary end point) was reported for 42.5% and 47.5% of the patients, respectively. The rates of major adverse cardiovascular events did not differ significantly between the two study groups. The rates of definite stent thrombosis were lower in the prehospital group than in the in-hospital group (0% vs. 0.8% in the first 24 hours; 0.2% vs. 1.2% at 30 days). Rates of major bleeding events were low and virtually identical in the two groups, regardless of the bleeding definition used